FDA 授予先声药业的 Sanbexin 舌下片剂突破性疗法称号，用于治疗中风。 FDA grants Breakthrough Therapy designation to Simcere's Sanbexin Sublingual Tablets for stroke treatment.
先声药业集团有限公司的 Sanbexin 舌下片剂获得了 FDA 的突破性疗法认定，这是同类药物中第一个用于治疗中风的药物。 Simcere Pharmaceuticals Group Ltd. has received Breakthrough Therapy designation from the FDA for its Sanbexin Sublingual Tablets, the first drug of its kind for stroke treatment. 这项指定旨在加快严重条件的发展。 This designation aims to expedite development for serious conditions. 将甲状腺素和脱氧乙醇相结合的Sanbexin表明,有望改善急性缺血性中风患者(最常见的中风类型)的治疗结果,每年影响全球数百万人。 Sanbexin, which combines edaravone and dexborneol, shows promise in improving outcomes for patients with acute ischemic stroke, the most common stroke type, impacting millions globally each year.